Pancreatic Cancer Research

ResearcherIndiana University HealthActive in the last 2 years

Christian Max Schmidt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2447-2128; OpenAlex author ID A5015843387; NIH RePORTER profile ID 8083154. Sources: OpenAlex.

Their work

Papers
28 (first author 1, last author 8)
Trials
0
Grants
2
Labs led
2
Collaborators
113
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 3 papers · 2014: none · 2015: 4 papers · 2016: 1 paper · 2017: 1 paper, 1 grant · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: none · 2023: 4 papers · 2024: 3 papers · 2025: 1 paper, 1 grant · 2026: 1 paper

Papers 28

  1. Assessing the interplay of operative volume at the hospital and surgeon level for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2026.07.007↗
  2. Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progress… Co-author DOI 10.1158/1078-0432.ccr-24-2931↗
  3. Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer. Co-author DOI 10.1093/clinchem/hvad186↗
  4. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  5. A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer. Co-author DOI 10.33696/cancerimmunol.6.095↗
  6. Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcomes in patients with pancreatic adenocarci… Co-author DOI 10.1016/j.surg.2022.06.046↗
  7. Amplification-Free, High-Throughput Nanoplasmonic Quantification of Circulating MicroRNAs in Unprocessed Plasma Microsamples for Earlier Pancreatic Cancer Dete… Co-author DOI 10.1021/acssensors.2c02105↗
  8. Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical … Co-author DOI 10.1097/mpa.0000000000002236↗
  9. Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an ea… Co-author DOI 10.1101/2023.08.14.553002↗
  10. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. First author DOI 10.1053/j.gastro.2020.11.052↗
  11. Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways. Co-author DOI 10.3390/cancers13081975↗
  12. Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy. Co-author DOI 10.1007/s11605-020-04723-2↗
  13. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression? Last author DOI 10.1016/j.amjsurg.2019.09.013↗
  14. Pancreatic Adenocarcinoma Causing Necrotizing Pancreatitis: Not as Rare as You Think? Co-author DOI 10.1016/j.jss.2019.12.036↗
  15. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Co-author DOI 10.1002/jcsm.12461↗
  16. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy126↗
  17. Laparoscopic distal pancreatectomy for pancreatic cancer is safe and effective. Co-author DOI 10.1007/s00464-017-5633-7↗
  18. Prospective Evaluation of Associations between Cancer-Related Pain and Perineural Invasion in Patients with Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-017-3513-z↗
  19. Significance of Portal Vein Invasion and Extent of Invasion in Patients Undergoing Pancreatoduodenectomy for Pancreatic Adenocarcinoma. Last author DOI 10.1007/s11605-015-3005-y↗
  20. Extended distal pancreatectomy for pancreatic adenocarcinoma with splenic vein thrombosis and/or adjacent organ invasion. Last author DOI 10.1016/j.amjsurg.2014.10.017↗
  21. Factors influencing the cytotoxicity of α-methylene-γ-hydroxy esters against pancreatic cancer. Co-author DOI 10.1016/j.bmcl.2015.07.087↗
  22. Automated pancreatic cyst screening using natural language processing: a new tool in the early detection of pancreatic cancer. Last author DOI 10.1111/hpb.12375↗
  23. Identification of Patients with Family History of Pancreatic Cancer--Investigation of an NLP System Portability. Co-author PMID 26262122↗
  24. Synthetic α-(aminomethyl)-γ-butyrolactones and their anti-pancreatic cancer activities. Co-author DOI 10.1016/j.bmcl.2013.09.065↗
  25. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Last author DOI 10.1097/mpa.0b013e318254f455↗
  26. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. Last author DOI 10.1186/1471-2407-13-194↗
  27. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. Last author DOI 10.1007/s11605-012-1913-7↗
  28. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to … Last author DOI 10.1016/j.jamcollsurg.2011.04.003↗

Grants 2

  1. Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer U01CA239522↗
  2. Identifying insulin resistance biomarkers and metabolomic signature as predictors of precursors to pancreatic cancer R21CA209366↗

Closest collaborators

The 25 strongest of 113 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianjun Zhang · 6 shared papers, 2 shared grants, 2017–2025 · strength 2.26
  2. Michele Yip-Schneider · 12 shared papers, 2012–2025 · strength 1.20
  3. Johannes Francois Fahrmann · 6 shared papers, 2019–2025 · strength 0.90
  4. Anirban Maitra · 6 shared papers, 2019–2025 · strength 0.90
  5. Michael Garrett House · 9 shared papers, 2015–2023 · strength 0.85
  6. Nicholas Joseph Zyromski · 9 shared papers, 2015–2023 · strength 0.85
  7. Eugene P. Ceppa · 9 shared papers, 2015–2023 · strength 0.85
  8. Ehsan Irajizad · 5 shared papers, 2021–2025 · strength 0.83
  9. Ricardo A. Léon-Letelier · 4 shared papers, 2023–2025 · strength 0.73
  10. Jody V. Vykoukal · 5 shared papers, 2019–2025 · strength 0.68
  11. Samir Hanash · 5 shared papers, 2019–2025 · strength 0.68
  12. Alexandra M. Roch · 6 shared papers, 2015–2023 · strength 0.47
  13. Riccardo Ballarò · 2 shared papers, 2024–2025 · strength 0.41
  14. Yihui Chen · 2 shared papers, 2023–2025 · strength 0.33
  15. Anthony D. Yang · 1 shared paper, 2026 · strength 0.32
  16. Ryan J. Ellis · 1 shared paper, 2026 · strength 0.32
  17. Dhruv J. Patel · 1 shared paper, 2026 · strength 0.32
  18. Rachel C. Kim · 2 shared papers, 2023–2024 · strength 0.31
  19. Trang K. Nguyen · 2 shared papers, 2020–2023 · strength 0.28
  20. Michael P. Kim · 2 shared papers, 2023–2024 · strength 0.26
  21. Katelyn F. Flick · 2 shared papers, 2020 · strength 0.23
  22. Rosalie A. Carr · 2 shared papers, 2017–2020 · strength 0.20
  23. Safi Shahda · 2 shared papers, 2019–2021 · strength 0.18
  24. Yunlong Liu · 2 shared papers, 2019–2021 · strength 0.18
  25. Xiaoling Zhong · 2 shared papers, 2019–2021 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.